Author: Margie Manning
Publisher: Tampa Bay Business Journal
Date: February 25, 2014
Tenacity is the key to funding for early-stage life science companies.
Burrill & Co., a San Francisco-based venture capital firm, sees several hundred business plans a month, and invested in one of every 150 last year, said CEO G. Steven Burrill at Moffitt Cancer Center’s Business of Biotech. “You have to kiss 100 frogs to find one prince.”
That’s where a stick-to-it attitude plays a role. Talking to a handful of venture capitalists isn’t enough, as Burrill explained in this video. “Maybe you have to talk to 100 or 200 [venture capitalists] to find one that’s interested.” Read more here.